1 The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing

- 2 Pavel Drevinek^{1*}, Jakub Hurych¹, Zdenek Kepka¹, Ales Briksi¹, Michal Kulich², Miroslav
- 3 Zajac¹, Petr Hubacek¹
- ¹Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol
- 5 University Hospital, Prague, Czech Republic
- ⁶ ²Deptartment of Probability and Statistics, Faculty of Mathematics and Physics, Charles
- 7 University, Prague, Czech Republic
- 8
- 9
- ^{*}Corresponding author
- 11 Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol
- 12 University Hospital; V Uvalu 84, 150 06 Prague, Czech Republic
- 13 pavel.drevinek@lfmotol.cuni.cz
- 14 tel. +420 22443 5350; fax +420 22443 5352

1 Abstract

2 Objectives: Antigen tests have recently emerged as an interesting alternative to SARS-CoV-3 2 diagnostic PCR, thought to be valuable especially for the screening of bigger communities. 4 To check appropriateness of the antigen based testing, we determined sensitivity of two 5 point-of-care antigen tests when applied to a cohort of COVID-19 symptomatic, COVID-19 6 asymptomatic and healthy persons. 7 Methods: We examined nasopharyngeal swabs with antigen test 1 (Panbio Covid-19 Ag 8 Rapid Test, Abbott) and antigen test 2 (Standard F Covid-19 Ag FIA, SD Biosensor). An 9 additional nasopharyngeal and oropharyngeal swab of the same individual was checked with 10 PCR (Allplex SARS-nCoV-2, Seegene). Within a 4-day period in October 2020, we collected 11 specimens from 591 subjects. Of them, 290 had COVID-19 associated symptoms. 12 Results: While PCR positivity was detected in 223 cases, antigen test 1 and antigen test 2 13 were found positive in 148 (sensitivity 0.664, 95% CI 0.599 - 0.722) and 141 (sensitivity 14 0.623, 95% CI 0.558 - 0.684) patients, respectively. When only symptomatic patients were 15 analysed, sensitivity increased to 0.738 (95% CI 0.667 - 0.799) for the antigen test 1 and to 16 0.685 (95% CI 0.611 - 0.750) for the antigen test 2. The substantial drop in sensitivity to 17 12.9% (95% CI 0.067 - 0.234) was observed for samples with the PCR threshold cycle above 18 > 30.

19 **Conclusions:** Low sensitivity of antigen tests leads to the considerable risk of false

20 negativity. It is advisable to implement repeated testing with high enough frequency if the

21 antigen test is used as a frontline screening tool.

22

1 Introduction

2	Early detection of SARS-CoV-2 infected individuals is a key factor for making the
3	containment measures effective. Since the beginning of the pandemic, a nucleic acid
4	detection by PCR has become a gold standard of a novel coronavirus disease (COVID-19)
5	diagnostics (1). However, not fast enough turnaround time, a need for laboratory equipment
6	and the shortage of reagents and plastic consumables raised concerns over the time about
7	the PCR as the only frontline tool for testing, especially in surveillance regimes where great
8	numbers of people need to be tested in relatively short time frames (2).
9	To overcome technical barriers associated with the use of PCR, point of care tests have
10	been considered to complement diagnostic PCR tests and to be used for fast and onsite
11	examination in various settings with suspected outbreaks of COVID-19. These include not
12	only institutions and semi-closed communities such as schools and care homes (WHO
13	interim guidance (3)), but even whole districts and countries, screened in the way of
14	population-wide testing (ECDC Report (4)).
15	An attractive candidate which meets the logistic criteria for mass testing is an antigen-based
16	detection of SARS-CoV-2 on the principle of immunochromatography. The test is
17	inexpensive, rapid, ready and easy to use. Nevertheless, rapid antigen tests have potential
18	limits in terms of low sensitivity that had been repeatedly documented for other respiratory
19	viruses (5). First reports on the performance of SARS-CoV-2 antigen detection indicated
20	similar findings (6-8), although the manufacturers of commercially available SARS-CoV-2
21	antigen tests commonly claim sensitivities over 90%. However, these values reflect results of
22	studies done on individuals who meet the criteria for the intended use of the kits, i.e.
23	diagnostics of COVID-19 in patients with clinical symptoms, not in a mixed population of
24	symptomatic, asymptomatic and healthy persons.

1 In our pilot study, we aimed to evaluate the performance of two antigen tests in a scenario

2 close to the population-wide testing. In this regard, we tested a group of nearly 600 people

- 3 who had no common epidemiological link between each other.
- 4

5 Methods

6 Subjects. Within a 4-day period in October 2020, we tested 591 individuals of 10 years of 7 age or older, who attended a single collection site, dedicated to the SARS-CoV-2 specimen 8 collection at the Motol University Hospital, Prague, Czech Republic, and consented to the 9 study. The main reasons for their SARS-CoV-2 collection site visit were either the suspicion 10 of COVID-19 infection (273 patients) or contact tracing (290 cases). While 511 persons were 11 referred by general practitioner or public health officer, 54 individuals were self-payers. The 12 mean age of the cohort was 40 years (age range 12 to 78 years), 44.7% were males. Nearly 13 one half of the population (290 subjects) self-reported presence of one or more of the 14 following symptoms: cough, pain of muscles and/or joints, chills, diarrhoea and/or vomiting, 15 elevated body temperature, loss of smell and/or taste. The study was approved by the 16 hospital Ethics Committee (ref no EK-1286/20).

17 Antigen tests and PCR. Upon the subject's consent, we sampled three separate 18 nasopharyngeal swabs and one additional swab from the oropharynx. Two nasopharyngeal 19 samples were used onsite for two antigen detection assays according to the manufacturers' 20 instructions: Panbio Covid-19 Ag Rapid Test (Abbott, Germany; hereafter referred to as "Ag 21 test 1") and Standard F Covid-19 Ag FIA (SD Biosensor, Republic of Korea; hereafter 22 referred to as "Ag test 2"). Briefly, the swab was first inserted into an extraction buffer 23 provided with the kit, then the amount of 5 (Ag test 1) or 4 drops (Ag test 2) was loaded on 24 the test device. The results were read after 15 minutes incubation at room temperature by a 25 naked eye (Ag test 1) or after 30 minutes incubation at room temperature on the bench (Ag 26 test 2) in the Standard F200 Analyser ('read-only' mode). In order not to unnecessarily lose

1 the sensitivity of the assays, we ran antigen tests immediately upon collecting the sample 2 and without the optional step of inserting the swab into the viral transport medium that may 3 lead in undesirable antigen dilution. 4 The remaining nasopharyngeal swab along with the oropharyngeal swab were sampled in 5 accordance with the international specimen collection guidelines (CDC, (9)). They were both 6 inserted into the viral transport medium (10) and transported to the hospital microbiology laboratory for the PCR analysis. RNA extraction was performed with Viral Nucleic Acid 7 8 Extraction kit (Zybio, China) on the EXM3000 instrument (Zybio, China). The extracts were 9 subjected to the reverse transcription PCR, targeting N, E and RdRP/S genes (Allplex SARS-10 nCoV-2; Seegene, Republic of Korea), run on the CFX96 PCR cycler (Bio-Rad, USA). The 11 sample was deemed positive if at least one of the genes was detected with a threshold cycle 12 (Ct) value < 40; to define a single Ct for a respective sample, we used the lowest Ct out of 13 the three detected targets.

1 Results

- 2 The PCR positivity was detected in 223 cases (37.7%). Out of them, 168 people had one or
- 3 more COVID-19 related symptoms (57.9% of all individuals with symptoms and 75.3% of all
- 4 PCR positive cases), while 55 PCR positive subjects reported no symptoms at the time of
- 5 sampling. Ag test 1 and Ag test 2 were found positive in 148 and 141 cases, respectively
- 6 (Table 1).
- 7 (a)

		PCR		
		positive	negative	Total
Ag test 1	positive	148	0	148
	negative	75	368	443
	Total	223	368	591
		Sensitivity 0.664	Specificity 1.000	
		(0.599 - 0.722)	(0.990 - 1.000)	

8

9 (b)

		PCR		
		positive	negative	Total
Ag test 2	positive	139	2	141
	negative	84	366	450
	Total	223	368	591
		Sensitivity 0.623	Specificity 0.995	
		(0.558 - 0.684)	(0.980 - 0.999)	

Table 1. Number of positive and negative results when Ag test 1 (Table 1a) and Ag test 2
 (Table 1b) are compared to PCR results. Sensitivity and specificity values are reported with
 95% CI (in brackets).

4 Test sensitivity increased to 0.738 (95% CI 0.667 - 0.799) for the Ag test 1 and to 0.685

5 (95% CI 0.611 - 0.750) for the Ag test 2 if only a subgroup of symptomatic patients (290

6 subjects) was analysed (data not shown). On the contrary, a low sensitivity value of 0.436

7 (95% CI 0.314 - 0.567) for either of the Ag tests was found in asymptomatic persons (301

8 subjects).

9 The likelihood of detecting the SARS-CoV-2 antigen in a PCR positive person increased with

decreasing PCR threshold cycle (Ct) (Table 2). The majority of PCR positive findings (161 of

12 223, i.e., 72%) had low Ct cycles < 30. In vast majority of cases, these PCR results belonged

12 to patients with COVID-19 associated symptoms (130 of 161 patients). Nevertheless, PCR

results with Ct > 30 also comprised mostly the symptomatic patients (38 of 62 cases).

14 Sensitivity of Ag tests was found greater than 80% only for samples with Ct < 30; a

substantial drop in sensitivity to mere 12.9% was observed for samples with Ct > 30.

16 (a)

PCR Ct	No pts	No symptomatic	No asymptomatic	Ag test 1	Ag test 2
		pts	pts	sensitivity	sensitivity
< 20	51	43	8	0.922	0.922
				(0.815-0.969)	(0.815-0.969)
< 25	121	99	22	0.926	0.901
				(0.865-0.960)	(0.835-0.942)
< 30	161	130	31	0.870	0.814
				(0.809-0.913)	(0.747-0.866)
< 35	190	154	36	0.779	0.726
				(0.715-0.832)	(0.659-0.785)

<u>≤</u> 40 223	168	55	see Table 1a	see Table 1b
-----------------	-----	----	--------------	--------------

1

2 (b)

PCR Ct	No pts	No symptomatic	No asymptomatic	Ag test 1	Ag test 2
		pts	pts	sensitivity	sensitivity
> 20	172	125	47	0.587	0.535
				(0.512-0.658)	(0.460-0.608)
> 25	102	69	33	0.353	0.294
				(0.267-0.450)	(0.214-0.389)
> 30	62	38	24	0.129	0.129
				(0.067-0.234)	(0.067-0.234)
> 35	33	14	19	0.0	0.03
				(0.0-0.104)	(0.005-0.153)

3

Table 2. Sensitivity of Ag test 1 and Ag test 2 in relation to the Ct if samples with higher Ct
are added to the samples with lower Ct (Table 2a), and if samples with lower Ct are taken
away from the samples with higher Ct (Table 2b).

7

1 Discussion

2	With the surge of the SARS-CoV-2 epidemic wave in autumn 2020, novel testing strategies
3	to tackle the community transmission are being sought, including the option of population-
4	wide screening with the aid of antigen tests (4). In our study, we mimicked a situation of
5	mass screening in that we tested each individual, attending the hospital COVID-19 collection
6	site, regardless of the presence or absence of clinical symptoms. Within 4 days, we enrolled
7	nearly 600 individuals out of 800 eligible people who were 10 years or older. Our PCR
8	positivity rate was almost 38% which was well in accordance with over 30% observed on a
9	national level at the time of the study performance (daily reports on (11)).
10	In our study, we worked with two different antigen tests out of which one enabled europium
11	fluorescence-based detection (Ag test 2), the detection that was believed to improve
12	sensitivity. However, this mode of result visualisation did not have any impact on the change
13	of sensitivity. Overall mean sensitivity values were 66.7% for Ag test 1 and 62.6% for Ag test
14	2. If the parameter of the presence of clinical symptoms is a criterion for performing the test,
15	sensitivity increased only modestly to 73.8% for Ag test 1 and 68.5% for Ag test 2, while it
16	dropped below 50% if asymptomatic, but PCR positive persons are tested.
17	Our findings fit well with the known sensitivity characteristics of antigen tests for other
18	respiratory viruses like influenza or respiratory syncytial virus where rapid
19	immunochromatography tests reach the sensitivity of 54.4% and 80%, respectively (12, 13).
20	Such discrepancies between sensitivity values reported in research articles and
21	manufacturers' leaflets come from differences in selection of tested samples. For instance, a
22	clinical evaluation of the Ag test 2 with the claimed sensitivity of 100% was performed on a
23	positive spiked material, not on real subjects. Interim data on Ag test 1 showed the sensitivity
24	of 85.5% (95% CI 78.2, 90.6), based on testing of 535 patients with suspicion of COVID-19
25	(14). Of them, 77% were checked by the antigen test within three days from the onset of the
26	symptoms, and 75% had their Ct < 25.

1 Similarly to Scohy et al. (8), we found out that the main attribute affecting the antigen test 2 sensitivity is a viral load as estimated by the Ct. Lower viral load, represented in our study by 3 high Ct values above 30, became hardly detectable by any of the two antigen tests used. 4 Thus, patients with samples of late Ct values would be largely left undiagnosed, although 5 many of them also presented with clinical symptoms in our study. Regardless of their clinical 6 state, it is important to point out that they all might be also infectious as documented in 7 studies on asymptomatic and presymptomatic persons (15, 16). 8 Because of the recent findings on infectivity (17), we can speculate that patients with low Ct 9 were actually at the end of their infection stage and no longer posed the risk to others. 10 However, our patient records show that only 5 of 62 patients with Ct > 30 visited the 11 collection site to monitor the course of their infection (3 of them had still clinical symptoms), 12 so we can assume that most of them were near the onset of the disease and cannot rule out 13 their infectivity. In reference to the aim of our study, i.e. to check the effectiveness of the 14 mass testing with antigen tests, another limitation of the study is the bias in selection of the 15 subjects who were in most cases indicated for the examination due to symptoms or contact 16 tracing. One can expect that the population-wide screening would include higher rate of 17 asymptomatic people with low viral loads as well as healthy persons which in turn would lead 18 in even higher false negativity and false positivity rates (18). 19 To conclude, in our opinion, the risk and rate of false negativity of antigen tests may have a 20 significant negative impact on the effectiveness of outbreaks containment as it is crucial to

early identify any positive person, including the ones with initially low viral load. Not to miss
them, a single round of testing, which is likely the case when a population-wide screening is
ordered, seems insufficient and inadequate. Instead, the strategy based on repeated testing
with high enough frequency (2) needs to be implemented if the antigen test is used as a
frontline screening tool.

1 Transparency declaration:

2 S	Supported by the Mi	istry of Health of the	Czech Republic - conce	ptual development of
-----	---------------------	------------------------	------------------------	----------------------

- 3 research organization Motol University Hospital, FNM. All authors report no conflicts of
- 4 interest relevant to this article.

5 Acknowledgements:

- 6 The authors are grateful to I. Adam, M. Sadilkova, K. Smolkova, M. Kalantay, I. Prosova, S.
- 7 Strba, D. Kovarikova, B. Dzerengova, A. Hutnan, A. Shaker, V. Casarova and other staff
- 8 members of Motol collection site for excellent technical assistance.

9

10 1. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.

11 JAMA. 2020;323:2249-51.

Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy
 for Containment. N Engl J Med. 2020.

14 3. WHO. Antigen detection in the diagnosis of SARS-CoV-2 infection using rapid

15 immunoassays 2020. Available from: https://www.who.int/publications/i/item/antigen-

16 detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays.

17 4. ECDC. Population-wide testing of SARS-CoV-2: country experiences and potential

approaches in the EU/EEA and the United Kingdom 2020. Available from:

19 https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-population-wide-testing-

20 country-experiences.pdf.

5. Azar MM, Landry ML. Detection of Influenza A and B Viruses and Respiratory

22 Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-

23 Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests. J Clin Microbiol.

24 2018;56.

1	6.	Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-
2	Afons	o AM, et al. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2
3	Antige	en in Nasopharyngeal Swabs. J Clin Microbiol. 2020;58.
4	7.	Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, et al. Evaluation of rapid
5	antige	en test for detection of SARS-CoV-2 virus. J Clin Virol. 2020;129:104500.
6	8.	Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A, Rodriguez-
7	Villalc	bos H. Low performance of rapid antigen detection test as frontline testing for COVID-
8	19 dia	agnosis. J Clin Virol. 2020;129:104455.
9	9.	CDC. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for
10	COVI	D-19 2020. Available from: https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-
11	clinica	al-specimens.html.
12	10.	Kim C, Ahmed JA, Eidex RB, Nyoka R, Waiboci LW, Erdman D, et al. Comparison of
13	nasop	pharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by
14	real-ti	me reverse transcription-PCR assays. PLoS One. 2011;6:e21610.
15	11.	Ministry of Health CR. COVID-19: The summary of current situation in Czech
16	Repul	blic. Available from: https://onemocneni-aktualne.mzcr.cz/covid-19.
17	12.	Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic
18	Accur	acy of Novel and Traditional Rapid Tests for Influenza Infection Compared With
19	Reve	rse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-
20	analys	sis. Ann Intern Med. 2017;167:394-409.
21	13.	Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic Accuracy of Rapid
22	Antige	en Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and
23	Meta-	analysis. J Clin Microbiol. 2015;53:3738-49.
24	14.	FIND. FIND Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device External
25	Repo	rt 2020 [Available from: https://finddx.org/wp-content/uploads/2020/11/Panbio_Ag-
26	Public	c-Report_v1_1.pdf.
27	15.	Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic
28	and P	resymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled

- 1 Nursing Facility King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep.
- 2 2020;69:377-81.
- 3 16. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al.
- 4 Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N
- 5 Engl J Med. 2020;382:2081-90.
- 6 17. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory
- 7 Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?
- 8 Clin Infect Dis. 2020.In press.
- 9 18. Sudlow C, Diggle P, Warlow O, Seymour D, Gordon B, Walker R, et al. Testing for
- 10 coronavirus (SARS-CoV-2) infection in populations with low infection prevalence: the largely
- ignored problem of false positives and the value of repeat testing. medRxiv. 2020.